{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:31:28Z","timestamp":1776457888311,"version":"3.51.2"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Heart Fail"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan is strongly supported in guidelines for the management of heart failure, but suboptimal adherence and treatment non\u2010persistence may limit the population\u2010level benefit that this therapy might otherwise offer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      We identified a cohort of Medicare beneficiaries (2014\u20132017) initiating sacubitril\/valsartan after \u22656\u00a0months of continuous enrolment. We assessed adherence as the proportion of days covered (PDC) and proportion of patients non\u2010persistent (having no prescription available) at 180\u2009days after initiation. We fit a multivariable negative binomial model with a count of adherent days to evaluate independent factors associated with of sacubitril\/valsartan adherence. Among 27\u2009063 new sacubitril\/valsartan users, most (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a017\u2009663, 65%) were prescribed low\u2010dose at 24\u2009mg\/26\u2009mg and most (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a019\u2009984, 74%) were switched from prior angiotensin\u2010converting enzyme inhibitor\/angiotensin receptor blocker (ACEi\/ARB) rather than being RASi treatment na\u00efve. Median 180\u2010day PDC was 86% (25th\u201375th percentiles 58\u201398%). Black patients, those with high comorbid disease burden (\u22658 comorbidities), and patients with recent hospitalization within 30\u2009days had fewer adherent days, while those treated with preceding ACEi\/ARB had more adherent days. Thirty\u2010four percent of patients did not have an active sacubitril\/valsartan prescription at day 180. Among these, few had preceding dose down\u2010titrations (6% among patients on 49\u2009mg\/51\u2009mg and 9% among patients on 97\u2009mg\/103\u2009mg) and 68% did not have a subsequent ACEi\/ARB prescription. Among patients who remained persistent, dose up\u2010titrations occurred in 29% of patients who started on 24\u2009mg\/26\u2009mg and 27% of patients on 49\u2009mg\/51\u2009mg.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall adherence to sacubitril\/valsartan among Medicare beneficiaries is acceptable, but is lower in Black patients, those with higher comorbidities or those who started therapy after recent hospitalization. While broad implementation of guideline\u2010directed medical therapy is a key priority, additional focused efforts to improve adherence early after hospitalization and among at\u2010risk patients are needed in parallel.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2572","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T08:40:11Z","timestamp":1654936811000},"page":"1506-1515","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sacubitril\/valsartan use patterns among older adults with heart failure in clinical practice: a\n                    <scp>population\u2010based<\/scp>\n                    cohort study of &gt;25\u2009000 Medicare beneficiaries"],"prefix":"10.1093","volume":"24","author":[{"given":"Ankeet S.","family":"Bhatt","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie C.","family":"Lauffenburger","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi J.","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.025"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.015"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2271"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.08.008"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004873"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.09.021"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.10.004"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1793312"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.09.268"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.06.018"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2333"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.06.073"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.02.011"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.860841"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-9-24"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1147"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.2822"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.022"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:15:58Z","timestamp":1767701758000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejhf.2572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/ejhf.2572"],"URL":"https:\/\/doi.org\/10.1002\/ejhf.2572","archive":["Portico"],"relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"2022-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}